UNSPSC 51281824: Zorubicin hydrochloride

This classification denotes an anthracycline antibiotic with the molecular formula C34H35N3O10.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WXM8D9M6DE, chemically known as rp-22,050 hydrochloride but more generally known as zorubicin hydrochloride, which bears US NIH Compound Identifier 6540456. European Medicines Agency schedules Zorubicin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05194MIG.

UNSPSC 51281824 Zorubicin hydrochloride is a Commodity code with minimal recent state and local procurement activity. The code nominally covers a specific chemotherapy drug, yet the most recent state and local opportunities tagged to this code show little direct alignment with oncology pharmaceuticals. Instead, the recent solicitations center on broader pharmaceutical procurement mechanisms: naloxone and drug deactivation systems, multi-source generics and OTC products through cooperative purchasing, and direct-to-manufacturer prescription programs. State and local buyers using this code span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), city fire departments (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The code shows activity primarily in Florida, Texas, and Minnesota, though MMCAP includes participating jurisdictions across multiple states.

Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, response deadline July 26, 2023); the Texas HHS Commission's Request for Information on direct-to-manufacturer prescription programs (posted April 3, 2026, exploring vendor capacity for self-insured group health plans and state agencies); the City of Tampa's IFB for medical and first aid supplies designated for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000 and a 5 percent small local business enterprise bid discount (response deadline March 13, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products available through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with proposals due March 26, 2026 and awards effective July 1, 2026. The mismatch between the code's pharmaceutical-specific name and the broader, non-specialty-drug scope of recent opportunities suggests this code may be misapplied by issuing bodies or represents legacy taxonomy usage in commodity procurement systems.